China Approves Merck KGaA's Pimicotinib for Tenosynovial Giant Cell Tumor
I'm PortAI, I can summarize articles.
Merck KGaA has received approval from China's NMPA for pimicotinib to treat tenosynovial giant cell tumor in adults, marking its first global regulatory approval. Developed by Abbisko Therapeutics, pimicotinib is a CSF-1R inhibitor. The approval is based on positive Phase 3 MANEUVER study results. Merck KGaA is seeking further regulatory filings in other markets. This AI-generated news brief is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments